Format

Send to

Choose Destination

See 1 citation found by title matching your search:

BMC Nephrol. 2018 Aug 22;19(1):212. doi: 10.1186/s12882-018-1000-8.

Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score.

Author information

1
Department of Transplantation Medicine, Oslo University Hospital Rikshospitalet, P.O. Box 4950, Nydalen, 0424, Oslo, Norway. aussif@hotmail.com.
2
Department of Transplantation Medicine, Oslo University Hospital Rikshospitalet, P.O. Box 4950, Nydalen, 0424, Oslo, Norway.
3
Calciscon AG, Bern, Switzerland.
4
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
5
Smerud Medical Research International AS, Oslo, Norway.
6
The Norwegian Renal Registry, Oslo University Hospital Rikshospitalet, Oslo, Norway.
7
Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway.

Abstract

BACKGROUND:

Cardiovascular complications are common in kidney transplant patients and calcification propensity of blood, measured as T50, is associated with cardiovascular outcomes. Paricalcitol supplementation affects calcium/phosphate homeostasis and may affect calcification propensity. To assess this hypothesis we measured T50 in kidney transplant recipients participating in a randomized study comparing paricalcitol versus no treatment during the first year after kidney transplantation.

METHODS:

Stored serum samples from 76 kidney transplant recipients (paricalcitol n = 37, no treatment n = 39) were analyzed. Analyses were performed at inclusion (8 weeks after transplantation) and repeated one year after transplantation.

RESULTS:

There were no statistically significant differences in T50 between the paricalcitol and placebo groups, neither at baseline (p = 0.56) nor at 1 year (p = 0.61). Also, there were no significant changes in T50 over time in either group or when pooling all data (p <  0.20). In multivariate regression analysis, out of 16 potentially relevant covariates, comprising clinical and biochemical parameters, only plasma PTH and T50 at baseline were significantly correlated to T50 after one year. (p <  0.03 and p < 0.01, respectively).

CONCLUSIONS:

Calcium propensity measured as T50 score remained unchanged with paricalcitol treatment in kidney transplant recipients, and was not changed over time during the study period of one year.

TRIAL REGISTRATION:

ClinicalTrials.gov, NCT01694160 , registered 23 September 2012.

KEYWORDS:

Calcification propensity score; Paricalcitol; Randomized controlled trial; Renal transplantation

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center